Renin-angiotensin system, hypertension, and chronic kidney disease: Pharmacogenetic implications

Journal of Pharmacological Sciences

Volumn 120, Issue 2, 2012, Pages 77-88

  Junior Lima Santos, Paulo Caleb ^a   Krieger, Jose Eduardo ^a   Pereira, Alexandre Costa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin converting enzyme inhibitor; Chronic kidney disease; Hypertension; Pharmacogenetics; Renin angiotensin system

Indexed keywords

EID: 84868029401     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12R03CR     Document Type: Review

References (125)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
2. Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008; 23:3851-3858.
3. Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004; 44:806-814.
4. Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep. 2010;12:335-341.
5. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49 2 Suppl 2:S12-S154.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1-S266.
8. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensinaldosterone system in chronic kidney disease. Am J Nephrol. 2010;31:541-550.
9. Titan SM, M Vieira J Jr, Dominguez WV, Barros RT, Zatz R. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. Clin Nephrol. 2011; 76:273-283.
10. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the reninangiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978;58:763-770.
11. Gavras H, Faxon DP, Berkoben J, Brunner HR, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation. 1978;58:770-776.
12. Nantel P, Rene de Cotret P. The evolution of angiotensin blockade in the management of cardiovascular disease. Can J Cardiol. 2010;26 Suppl E:7E-13E.
13. Nishiyama A, Kim-Mitsuyama S. New approaches to blockade of the renin-angiotensin-aldosterone system: overview of regulation of the renin-angiotensin-aldosterone system. J Pharmacol Sci. 2010;113:289-291.
14. Gribouval O, Gonzales M, Neuhaus T, Aziza J, Bieth E, Laurent N, et al. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. Nat Genet. 2005;37:964-968.
15. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010;160:1273-1292.
16. Zivna M, Hulkova H, Matignon M, Hodanova K, Vylet'al P, Kalbacova M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Hum Genet. 2009;85:204-213.
17. Hillermann R, Carelse K, Gebhardt GS. The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. J Hum Genet. 2005;50:415-419.
18. Menard J, Bouhnik J, Clauser E, Richoux JP, Corvol P. Biochemistry and regulation of angiotensinogen. Clin Exp Hypertens A. 1983;5:1005-1019.
19. Nakajima T, Wooding S, Sakagami T, Emi M, Tokunaga K, Tamiya G, et al. Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world. Am J Hum Genet. 2004;74:898-916.
20. Pereira TV, Nunes AC, Rudnicki M, Yamada Y, Pereira AC, Krieger JE. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T? Hypertension. 2008;51:778-783.
21. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
22. Corvol P, Michaud A, Soubrier F, Williams TA. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J Hypertens Suppl. 1995;13:S3-S10.
23. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747-803.
24. Arbustini E, Grasso M, Fasani R, Klersy C, Diegoli M, Porcu E, et al. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J. 1995;74:584-591.
25. Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes. 1994;43:690-695.
26. Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology. 2004;62: 363-368.
27. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha LD, et al. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun. 2004;323:1124-1129.
28. Oike Y, Hata A, Ogata Y, Numata Y, Shido K, Kondo K. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. J Clin Invest. 1995;96:2975-2979.
29. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, et al. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest. 1995; 96:2162-2169.
30. Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011;29:509-519.
31. Beitelshees AL, Zineh I. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management. Heart Fail Rev. 2010;15:209-217.
32. Nguyen G. Renin and prorenin receptor in hypertension: what's new? Curr Hypertens Rep. 2011;13:79-85.
33. Savoia C, D'Agostino M, Lauri F, Volpe M. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20:125-132.
34. Kobashi G, Hata A, Ohta K, Yamada H, Kato EH, Minakami H, et al. A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. J Hum Genet. 2004; 49:182-186.
35. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3? untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet. 2007; 81:405-413.
36. Erdos EG, Tan F, Skidgel RA. Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function. Hypertension. 2010;55:214-220.
37. Sharma JN. Cardiovascular activities of the bradykinin system. ScientificWorldJournal. 2008;8:384-393.
38. Hallberg P, Lind L, Michaelsson K, Karlsson J, Kurland L, Kahan T, et al. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2003;21:621-624.
39. Lung CC, Chan EK, Zuraw BL. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol. 1997;99(1 Pt 1):134-146.
40. Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A. 1992;89:4996-5000.
41. Alvarez-Madrazo S, Connell JM, Freel EM. Role of genetic variation in regulation of aldosterone biosynthesis. Endocr Dev. 2011;20:106-115.
42. Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ, Ferrari P. A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab. 2003;88:2495-2500.
43. Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18:3506-3515.
44. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2006;281:35137-35146.
45. De Mello WC, Frohlich ED. On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides. 2011; 32:1774-1779.
46. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol. 2003;14:1738-1747.
47. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens. 2009;18: 33-39.
48. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab. 2007;18:208-214.
49. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucoseinduced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H939-H948.
50. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273(4 Pt 2):H1769-H1774.
51. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
52. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43: 699-706.
53. Ritz E, Adamczak M, Zeier M. Kidney and hypertension-causes. Update 2003. Herz. 2003;28:663-667.
54. Bidani AK, Griffin KA. Long-term renal consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens. 2002;11:73-80.
55. Susic D. Renal protective potential of antihypertensive drugs. Expert Opin Investig Drugs. 2000;9:2593-2600.
56. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs. 2005;65 Suppl 2:29-39.
57. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857-1863.
58. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
59. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
60. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601-1608.
61. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
62. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, et al. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren. J Pharmacol Sci. 2010;113: 296-300.
63. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329: 1456-1462.
64. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet. 1998;352:1252-1256.
65. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951.
66. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17:3472-3481.
67. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressureindependent effect. Circulation. 2002;106:672-678.
68. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
69. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64:999-1028.
70. Schjoedt KJ. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone. Dan Med Bull. 2011;58:B4265.
71. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004; 47:1936-1939.
72. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224-236.
73. Ueda S. New approaches to blockade of the renin-angiotensinaldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers-questions remain unsolved. J Pharmacol Sci. 2010;113:292-295.
74. Yarows SA. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Rev Cardiovasc Ther. 2010;8:19-33.
75. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
76. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32:1873-1879.
77. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73:1419-1425.
78. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Ther Clin Risk Manag. 2009;5:459-464.
79. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
80. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
81. Azizi M, Frank M, Steichen O, Blanchard A. [Advantages and limitations of renin inhibition with aliskiren]. Ann Pharm Fr. 2011;69:142-150. (in French) 82 Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints ( ALTITUDE). J Renin Angiotensin Aldosterone Syst. In press.
82. Sullivan JC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1220-R1226.
83. Titan SM, Pereira AC, Cunha RS, Herkenhoff FL, Mill JG, Krieger JE. Renin-angiotensin system polymorphisms interact with blood pressure in the determination of microalbuminuria in the general population. J Hum Hypertens. 2006;20:235-237.
84. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993;290(Pt 1):33-40.
85. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
86. Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM, Krieger JE. ACE gene dosage modulates pressure-induced cardiac hypertrophy in mice and men. Physiol Genomics. 2006;27:237-244.
87. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes. 1998;47: 1507-1511.
88. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 1998; 53:1002-1006.
89. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003; 14:2843-2850.
90. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ. 1996;313:591-594.
91. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, et al. Angiotensin- converting enzyme (ACE) inhibition in type 2, diabetic patients-interaction with ACE insertion/deletion polymorphism. Kidney Int. 2006;69:1438-1443.
92. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol. 2008;19:771-779.
93. Nonoguchi H, Nakayama Y, Shiigai T, Inoue T, Inoue H, Kohda Y, et al. Low-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme. Clin Nephrol. 2007;68:209-215.
94. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008;3:1511-1525.
95. Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL. ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 1998;98:2148-2153.
96. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens. 2001;19:1783-1787.
97. Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007;25:2082-2092.
98. Filigheddu F, Argiolas G, Bulla E, Troffa C, Bulla P, Fadda S, et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics. 2008;9:1419-1427.
99. Yu H, Zhang Y, Liu G. Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res. 2003;26:881-886.
100. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374-3383.
101. Konoshita T, Kato N, Fuchs S, Mizuno S, Aoyama C, Motomura M, et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care. 2009;32:1485-1490.
102. Nordestgaard BG, Kontula K, Benn M, Dahlof B, de Faire U, Edelman JM, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics. 2010;20:77-85.
103. Redon J, Luque-Otero M, Martell N, Chaves FJ. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J. 2005;5:14-20.
104. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
105. Pereira AC, Mota GF, Cunha RS, Herbenhoff FL, Mill JG, Krieger JE. Angiotensinogen 235T allele "dosage" is associated with blood pressure phenotypes. Hypertension. 2003;41:25-30.
106. Schelleman H, Klungel OH, Witteman JC, Breteler MM, Yazdanpanah M, Danser AH, et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet. 2007;15:478-484.
107. Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation. 2007;115:725-732.
108. Hannila-Handelberg T, Kontula KK, Paukku K, Lehtonen JY, Virtamo J, Tikkanen I, et al. Common genetic variations of the renin-angiotensin- aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension. J Hypertens. 2010;28:771-779.
109. Yu H, Lin S, Liu G, Zhang Y, Deng C, Ma W. T1198C polymorphism of the angiotensinogen gene and antihypertensive response to angiotensin-converting enzyme inhibitors. Hypertens Res. 2005;28:981-986.
110. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994; 24:63-69.
111. Wu CK, Tsai CT, Chang YC, Luo JL, Wang YC, Hwang JJ, et al. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens. 2009;27:502-507.
112. Xu M, Sham P, Ye Z, Lindpaintner K, He L. A1166C genetic variation of the angiotensin II type I receptor gene and susceptibility to coronary heart disease: collaborative of 53 studies with 20,435 cases and 23,674 controls. Atherosclerosis. 2010;213: 191-199.
113. Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association ( PERGENE) study. Neth Heart J. 2012;20:24-32.
114. Brunner M, Cooper-DeHoff RM, Gong Y, Karnes JH, Langaee TY, Pepine CJ, et al. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am J Cardiol. 2007;99:1549-1554.
115. Yu H, Lin S, Jin L, Yu Y, Zhong J, Zhang Y, et al. Adenine/cytosine( 1166) polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J Hypertens. 2009;27:2278-2282.
116. Moore N, Dicker P, O'Brien JK, Stojanovic M, Conroy RM, Treumann A, et al. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. Hypertension. 2007;50:340-347.
117. Yan W, Zhang Y, Shan Z, Wang Q, Huang Y, Wang C, et al. Tagging SNPs in REN, AGTR1 and AGTR2 genes and response of renin activity, angiotensin II and aldosterone concentrations to antihypertensive treatment in Kazakans. J Renin Angiotensin Aldosterone Syst. 2011;12:581-587.
118. Fan X, Wang Y, Sun K, Zhang W, Yang X, Wang S, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007;82:187-196.
119. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensinconverting enzyme inhibitor-related cough. Hypertension. 2000; 36:127-131.
120. Jiang X, Sheng HH, Lin G, Li J, Lu XZ, Cheng YL, et al. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chin Med J (Engl). 2007;120:782-786.
121. Farahani P, Dolovich L, Levine M. Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension. J Clin Epidemiol. 2007;60:1-7.
122. Konoshita T. Do genetic variants of the renin-angiotensin system predict blood pressure response to renin-angiotensin systemblocking drugs?: a systematic review of pharmacogenomics in the renin-angiotensin system. Curr Hypertens Rep. 2011;13: 356-361.
123. Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J. 2010;31: 1854-1864.
124. Santos PC, Alvim Rde O, Ferreira NE, de Sa Cunha R, Krieger JE, Mill JG, et al. Ethnicity and arterial stiffness in Brazil. Am J Hypertens. 2011;24:278-284.
125. Santos PC, Gagliardi AC, Miname MH, Chacra AP, Santos RD, Krieger JE, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012;68:273-279.